<VariationArchive VariationID="2035946" VariationName="NM_001429.4(EP300):c.4947dup (p.Ser1650fs)" VariationType="Duplication" Accession="VCV002035946" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-20" DateCreated="2023-02-08" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2093863" VariationID="2035946">
      <GeneList>
        <Gene Symbol="EP300" FullName="E1A binding protein p300" GeneID="2033" HGNC_ID="HGNC:3373" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>22q13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="41092592" stop="41180077" display_start="41092592" display_stop="41180077" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="41488613" stop="41576080" display_start="41488613" display_stop="41576080" Strand="+" />
          </Location>
          <OMIM>602700</OMIM>
          <Haploinsufficiency last_evaluated="2013-03-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=EP300">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2013-03-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=EP300">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_001429.4(EP300):c.4947dup (p.Ser1650fs)</Name>
      <CanonicalSPDI>NC_000022.11:41176412:GG:GGG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>22q13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="41176412" stop="41176413" display_start="41176412" display_stop="41176413" variantLength="1" positionVCF="41176412" referenceAlleleVCF="T" alternateAlleleVCF="TG" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="41572416" stop="41572417" display_start="41572416" display_stop="41572417" variantLength="1" positionVCF="41572416" referenceAlleleVCF="T" alternateAlleleVCF="TG" />
      </Location>
      <ProteinChange>S1624fs</ProteinChange>
      <ProteinChange>S1650fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1422" sequenceAccession="LRG_1422">
            <Expression>LRG_1422:g.88805dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1422t1" sequenceAccession="LRG_1422t1">
            <Expression>LRG_1422t1:c.4947dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1422p1" sequenceAccession="LRG_1422p1" change="p.Ser1650fs">
            <Expression>LRG_1422p1:p.Ser1650fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.10" sequenceAccession="NC_000022" sequenceVersion="10" change="g.41572418dup" Assembly="GRCh37">
            <Expression>NC_000022.10:g.41572418dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.11" sequenceAccession="NC_000022" sequenceVersion="11" change="g.41176414dup" Assembly="GRCh38">
            <Expression>NC_000022.11:g.41176414dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009817.1" sequenceAccession="NG_009817" sequenceVersion="1" change="g.88805dup">
            <Expression>NG_009817.1:g.88805dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001362843.2" sequenceAccession="NM_001362843" sequenceVersion="2" change="c.4869dup">
            <Expression>NM_001362843.2:c.4869dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001349772.1" sequenceAccession="NP_001349772" sequenceVersion="1" change="p.Ser1624fs">
            <Expression>NP_001349772.1:p.Ser1624fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001429.4" sequenceAccession="NM_001429" sequenceVersion="4" change="c.4947dup" MANESelect="true">
            <Expression>NM_001429.4:c.4947dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001420.2" sequenceAccession="NP_001420" sequenceVersion="2" change="p.Ser1650fs">
            <Expression>NP_001420.2:p.Ser1650fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_001429.4(EP300):c.4947dup (p.Ser1650fs) AND Rubinstein-Taybi syndrome due to EP300 haploinsufficiency" Accession="RCV002894592" Version="2">
        <ClassifiedConditionList TraitSetID="6729">
          <ClassifiedCondition DB="MedGen" ID="C3150941">Rubinstein-Taybi syndrome due to EP300 haploinsufficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-10-19" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-10-19" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-08" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">17299436</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="6729" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="15794" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Rubinstein-Taybi syndrome 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Rubinstein-Taybi syndrome due to EP300 haploinsufficiency</ElementValue>
                <XRef ID="MONDO:0013364" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">EP300</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">RSTS2</ElementValue>
                <XRef Type="MIM" ID="613684" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Rubinstein-Taybi syndrome (RSTS) is characterized by distinctive facial features, broad and often angulated thumbs and halluces, short stature, and moderate-to-severe intellectual disability. The characteristic craniofacial features are downslanted palpebral fissures, low-hanging columella, high palate, grimacing smile, and talon cusps. Prenatal growth is often normal, then height, weight, and head circumference percentiles rapidly drop in the first few months of life. Short stature is typical in adulthood. Obesity may develop in childhood or adolescence. Average IQ ranges between 35 and 50; however, developmental outcome varies considerably. Some individuals with EP300-RSTS have normal intellect. Additional features include ocular abnormalities, hearing loss, respiratory difficulties, congenital heart defects, renal abnormalities, cryptorchidism, feeding problems, recurrent infections, and severe constipation.</Attribute>
                <XRef ID="NBK1526" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17535" />
                <XRef ID="17535" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301699</ID>
                <ID Source="BookShelf">NBK1526</ID>
              </Citation>
              <XRef ID="353284" DB="Orphanet" />
              <XRef ID="783" DB="Orphanet" />
              <XRef ID="C3150941" DB="MedGen" />
              <XRef ID="MONDO:0013364" DB="MONDO" />
              <XRef Type="MIM" ID="613684" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5930368" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="17751276|MedGen:C3150941" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003240998" DateUpdated="2024-02-20" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-10-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">17299436</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the EP300 protein in which other variant(s) (p.Pro2367Argfs*36) have been determined to be pathogenic (PMID: 17299436). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with EP300-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Ser1650Valfs*23) in the EP300 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 765 amino acid(s) of the EP300 protein.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="EP300" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000022.10:g.41572416_41572417insG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3150941" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5930368" TraitType="Disease" MappingType="XRef" MappingValue="C3150941" MappingRef="MedGen">
        <MedGen CUI="C3150941" Name="Rubinstein-Taybi syndrome due to EP300 haploinsufficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

